Global Fabry Disease Drugs Market 2024-2028

The fabry disease drugs market is forecasted to grow by USD 859.06 mn during 2023-2028, accelerating at a CAGR of 7.43% during the forecast period. The report on the fabry disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of rare diseases, availability of incentives for development of orphan drugs, and growing focus on research and development and FDA approval of fabry disease drugs.

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.83%
CAGR	7.43%
Incremental Value	$859.06mn

Technavio's fabry disease drugs market is segmented as below:

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Route Of Administration

Intravenous route
Oral route

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the focus on strategic alliances and partnerships as one of the prime reasons driving the fabry disease drugs market growth during the next few years. Also, geopolitical uncertainties in global fabry disease drugs market and growing number of awareness programs for fabry disease will lead to sizable demand in the market.

The report on the fabry disease drugs market covers the following areas:

Fabry disease drugs market sizing
Fabry disease drugs market forecast
Fabry disease drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading fabry disease drugs market vendors that include 4D Molecular Therapeutics Inc., Amicus Therapeutics Inc., CHIESI Farmaceutici SpA, Freeline Therapeutics Holdings plc, Idorsia Pharmaceuticals Ltd., Sangamo Therapeutics Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.. Also, the fabry disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR77260

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global fabry disease drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global fabry disease drugs market 2018 - 2022 ($ million)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.3 Route Of Administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ million)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Route of Administration

7.1 Market segments
Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 50: Chart on Comparison by Route of Administration
Exhibit 51: Data Table on Comparison by Route of Administration
7.3 Intravenous route - Market size and forecast 2023-2028
Exhibit 52: Chart on Intravenous route - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Intravenous route - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Intravenous route - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Intravenous route - Year-over-year growth 2023-2028 (%)
7.4 Oral route - Market size and forecast 2023-2028
Exhibit 56: Chart on Oral route - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Oral route - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Oral route - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Oral route - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Route of Administration
Exhibit 60: Market opportunity by Route of Administration ($ million)
Exhibit 61: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 4D Molecular Therapeutics Inc.
Exhibit 111: 4D Molecular Therapeutics Inc. - Overview
Exhibit 112: 4D Molecular Therapeutics Inc. - Product / Service
Exhibit 113: 4D Molecular Therapeutics Inc. - Key offerings
12.4 Amicus Therapeutics Inc.
Exhibit 114: Amicus Therapeutics Inc. - Overview
Exhibit 115: Amicus Therapeutics Inc. - Product / Service
Exhibit 116: Amicus Therapeutics Inc. - Key offerings
12.5 CHIESI Farmaceutici SpA
Exhibit 117: CHIESI Farmaceutici SpA - Overview
Exhibit 118: CHIESI Farmaceutici SpA - Product / Service
Exhibit 119: CHIESI Farmaceutici SpA - Key offerings
12.6 Freeline Therapeutics Holdings plc
Exhibit 120: Freeline Therapeutics Holdings plc - Overview
Exhibit 121: Freeline Therapeutics Holdings plc - Product / Service
Exhibit 122: Freeline Therapeutics Holdings plc - Key offerings
12.7 Idorsia Pharmaceuticals Ltd.
Exhibit 123: Idorsia Pharmaceuticals Ltd. - Overview
Exhibit 124: Idorsia Pharmaceuticals Ltd. - Product / Service
Exhibit 125: Idorsia Pharmaceuticals Ltd. - Key offerings
12.8 Sangamo Therapeutics Inc.
Exhibit 126: Sangamo Therapeutics Inc. - Overview
Exhibit 127: Sangamo Therapeutics Inc. - Product / Service
Exhibit 128: Sangamo Therapeutics Inc. - Key offerings
12.9 Sanofi SA
Exhibit 129: Sanofi SA - Overview
Exhibit 130: Sanofi SA - Business segments
Exhibit 131: Sanofi SA - Key news
Exhibit 132: Sanofi SA - Key offerings
Exhibit 133: Sanofi SA - Segment focus
12.10 Takeda Pharmaceutical Co. Ltd.
Exhibit 134: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 135: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 136: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 137: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 138: Inclusions checklist
Exhibit 139: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 140: Currency conversion rates for US$
13.4 Research methodology
Exhibit 141: Research methodology
Exhibit 142: Validation techniques employed for market sizing
Exhibit 143: Information sources
13.5 List of abbreviations
Exhibit 144: List of abbreviations